Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS NBI Initiates PIII Study for BIBF1122 in Japan
September 12, 2011
-
REGULATORY MHLW Director-General Kikura Indicates “Firm Resolve” for Structural Improvement to Eliminate Drug Disasters
September 12, 2011
-
ACADEMIA Clinical Positioning Needs to Be Clarified for Nexavar, Sutent: Prof. Naito of Kyushu Univ.
September 12, 2011
-
REGULATORY MHLW’s Council to Draw Up 10-Year Strategy for Hepatitis
September 9, 2011
-
REGULATORY Council Recommends Subsidization of Peginterferon Therapy for Chronic Active Hepatitis B
September 9, 2011
-
BUSINESS Eisai to Accelerate Clinical Development with Milestone Payments, Signs Agreement on PIII Trials for Lenvatinib
September 8, 2011
-
REGULATORY CSIMC Introduces New Rule for Pricing of High-Priced Drugs; 10 Drugs to Be Reimbursed on Piecework under DPC
September 8, 2011
-
REGULATORY Some CSIMC Members Question NHI Pricing of Nexium Priced at Lower Level Than Omepral
September 8, 2011
-
REGULATORY CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
September 7, 2011
-
ACADEMIA ”Seller’s Market” for Pharmacists Expected to Continue Over Next Few Years
September 7, 2011
-
ORGANIZATION JGA to Prepare Transparency GLs
September 6, 2011
-
ORGANIZATION Gaining Piece of the Pie in Growing Market “Best for Fast Results”: Keizai Doyukai’s Hasegawa
September 6, 2011
-
REGULATORY Pharmaceutical Industry Fully Sufficient as Export Industry: METI Minister Hachiro
September 5, 2011
-
REGULATORY MHLW Minister Komiyama to Focus on Social Security Reform
September 5, 2011
-
REGULATORY Noda Cabinet: MHLW Vice Minister Komiyama Promoted to Minister
September 5, 2011
-
BUSINESS Daiichi Sankyo Espha Asks Patent Office to Invalidate Combination Patents for Takeda’s Actos
September 2, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…